Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.
[powerpress]
Acquired Resistance Forum Video #5: Dr. Gideon Blumenthal of the US Food and Drug Administration (FDA) discussed the FDA process for approving targeted therapies.
[powerpress]
Acquired Resistance Forum Video #4: The first three speakers at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
[powerpress]
Acquired Resistance Forum Video #3: Dr. Lecia Sequist of Massachusetts General Hospital detailed why doctors started doing repeat biopsies for patients receiving targeted therapies and how they help patients and doctors determine next steps in treatment.
[powerpress]
Dr. Jared Weiss of the University of North Carolina addressed the Acquired Resistance in Lung Cancer Patient Forum with information on what patients' options are when their ALK, ROS1 or EGFR lung cancer progresses.
Acquired Resistance Forum Video #1: Dr. Gregory J. Riely of Memorial Sloan Kettering Cancer Center opened the Acquired Resistance in Lung Cancer Patient Forum with a basic introduction of how ALK, ROS1 and EGFR lung cancers become resistant to treatment.
Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan discuss the excitement the medical community is feeling about immunotherapy for the treatment of lung cancer. February 2014
[powerpress]
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
[powerpress]
For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier.
For patients with wild type EGFR, meaning there is no EGFR mutation, drugs like Tarceva (erlotinib) can have a small benefit, but Dr. Joan Schiller wants research to do better. February 2014
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.